Ikarian Capital, LLC Monte Rosa Therapeutics, Inc. Transaction History
Ikarian Capital, LLC
- $573 Million
- Q3 2024
A detailed history of Ikarian Capital, LLC transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 311,593 shares of GLUE stock, worth $2.65 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
311,593Holding current value
$2.65 Million% of portfolio
0.29%Shares
1 transactions
Others Institutions Holding GLUE
# of Institutions
83Shares Held
43.9MCall Options Held
141KPut Options Held
31.2K-
Nea Management Company, LLC Timonium, MD7.69MShares$65.3 Million3.11% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.6MShares$56 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.79MShares$49.2 Million0.46% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$41.7 Million0.28% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.66MShares$22.6 Million0.55% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $397M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...